Inside the White House with D.C.'s most wired reporter. Sign up for Mike Allen's Axios AM.

Stories

The cost of gene therapies could test the health care system

Gene cell thaerapy
YposKesi, a pharmaceutical company produces gene and cell therapy drugs for rare diseases. Photo: Erix Piermont/AFP/Getty Images

There are hundreds of gene therapies in the development pipeline, raising the question of how these drugs — which could have price tags upwards of $1 million — will be paid for, and whether our system is built to handle that, the Wall Street Journal reports.

Details: These gene therapies could treat or cure illnesses that currently cost the system even more over time, via long-term maintenance drugs.

  • Other drugs serve small populations and have huge benefits. Luxturna, a drug that's already approved, treats a hereditary disease that causes blindness, but has a list price of $425,000 per eye.
  • Wall Street expects that these drugs will generate billions in revenue.

But even if these costs are justified, our health care system isn't designed for large, one-time payments.

  • Medicare and Medicaid aren't allowed to pay for drugs in installments.
  • Private insurers usually only insure a patient for a few years at a time. This means they don't reap the long-term savings from these therapies.

Go deeper: What to watch for with gene therapy

More stories loading.